Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Sleep peptides research covers two distinct mechanisms: compounds that directly modulate slow-wave sleep architecture (DSIP, Epitalon) and compounds that amplify the nocturnal growth hormone pulse that occurs during deep sleep (CJC-1295, Ipamorelin). This guide covers four of the most-studied compounds — mechanisms, what the evidence actually shows, and the current regulatory picture. Two of them are on the FDA Pharmacy Compounding Advisory Committee (PCAC) docket for the July 23–24, 2026 advisory meeting.
FDA PCAC Advisory Meeting — July 23–24, 2026
DSIP and Epitalon are two of seven peptides on the FDA Pharmacy Compounding Advisory Committee (PCAC) docket for the July 23–24, 2026 meeting. The PCAC makes recommendations for the 503A Bulk Drug Substances List — the FDA issues any final rule later. In April 2026, the FDA removed DSIP and Epitalon (among 12 peptides) from Category 2 (the significant-safety-concern list), but this does not authorize compounding or place either compound on the Category 1 list. Track the regulatory status →
| Peptide | Sleep Mechanism | Evidence Base | 2026 Status | PCAC July 2026? |
|---|---|---|---|---|
| DSIP | Slow-wave sleep promotion, HPA axis modulation | Human trials (1977–1984) | PCAC docket | On docket |
| Epitalon | Pineal melatonin restoration, circadian entrainment | Russian clinical cohorts | PCAC docket | On docket |
| CJC-1295 | GHRH analog — nocturnal GH pulse amplification | Phase 2 human PK data (GH endpoint) | Cat-2 removed Apr 2026 | — |
| Ipamorelin | Selective GHRP — GH pulse, no cortisol elevation | Preclinical + Phase 1 selectivity data | Cat-2 removed Apr 2026 | — |
Endogenous delta-sleep neuropeptide — the original sleep peptide
DSIP (Delta Sleep Inducing Peptide; Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is an endogenous nonapeptide first isolated from the cerebral venous blood of sleeping rabbits by Monnier, Dudler, and Gächter in 1977. It is found in the hypothalamus, limbic system, and pituitary, and is released into cerebrospinal fluid and blood during sleep. The primary mechanism is promotion of slow-wave sleep (NREM stages 3–4, also called delta sleep) — the deepest and most restorative phase of the sleep cycle. DSIP also modulates the hypothalamic-pituitary-adrenal (HPA) axis: it inhibits corticotropin (ACTH) release, reducing stress-induced cortisol elevation. This HPA modulation may partly explain its sleep-promoting effects, since elevated evening cortisol is a common driver of insomnia and fragmented sleep. DSIP also inhibits somatostatin (growth hormone-inhibiting hormone), which may permit more robust nocturnal GH release.
The foundational evidence for DSIP is the Monnier group's 1977 isolation paper and the subsequent Schoenenberger et al. (1978, European Neurology) double-blind crossover study in human subjects, which reported increased slow-wave sleep duration. Graf and Kastin reviewed the human evidence in 1984 (Neuroscience & Biobehavioral Reviews), documenting sleep-improving effects across six human trials. Important limitations: the primary evidence base is from 1977–1984; DSIP has a plasma half-life measured in minutes, which raises questions about how peripheral administration reaches the CNS; blood-brain barrier penetration is contested in the pharmacokinetics literature. No large-scale modern randomized controlled trials have been conducted. The research interest in DSIP was largely overtaken by pharmaceutical sleep aids in the 1990s, leaving a scientifically interesting but incompletely characterized compound.
Pineal tetrapeptide — circadian melatonin restoration
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from Epithalamin, a natural polypeptide extracted from the bovine pineal gland. Unlike DSIP, which acts on sleep directly, Epitalon targets the circadian clock at its source: it stimulates the pineal gland to restore normal melatonin synthesis. The pineal gland is the master circadian transducer — it converts photic (light/dark) signals into melatonin pulses that entrain the sleep-wake cycle. With advancing age, pineal function declines, reducing both the amplitude and timing precision of melatonin secretion. This circadian drift contributes to the age-related deterioration of sleep quality — delayed sleep onset, reduced slow-wave sleep, and fragmented nocturnal sleep. Epitalon also activates telomerase (its primary longevity mechanism), but in the sleep context its most relevant action is normalizing melatonin synthesis rather than supplementing it from outside — a mechanistically different approach from exogenous melatonin supplementation.
Khavinson and Anisimov (Ageing Research Reviews, 2010) summarized two decades of Epitalon research, including data showing normalization of melatonin secretion in aged animals. Arutjunyan et al. (2001, Journal of Gerontology: Biological Sciences) documented that Epitalon restored the amplitude and nighttime peak of melatonin in aged female rats to levels closer to young controls. A small human cohort study (Khavinson et al., 2002, Neuro Endocrinology Letters) reported improvements in sleep quality and melatonin rhythms in elderly subjects treated with Epitalon. Limitations: the human evidence base is entirely from Russian institutional studies by the peptide's developers; sample sizes are small; no independent Western replication trials exist; the mechanistic pathway from tetrapeptide to pineal melatonin synthesis upregulation is not fully characterized at the molecular receptor level.
GHRH analog — amplifies the nocturnal GH pulse
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates the anterior pituitary to release growth hormone. In its most studied form (CJC-1295 with DAC — Drug Affinity Complex), it is modified with a lysine-maleimide linker that binds covalently to serum albumin, extending its half-life from minutes to approximately one week. The sleep-research relevance of CJC-1295 is indirect but well-grounded: growth hormone is secreted in pulses, and the largest pulse in healthy adults occurs within the first hour of sleep onset — during the first bout of slow-wave (NREM stage 3) sleep. CJC-1295 amplifies the amplitude of GH pulses without altering their pulsatile frequency, effectively boosting the nocturnal GH release that is associated with cellular repair, body composition maintenance, and immune function during sleep.
Ionescu and Frohman (Journal of Clinical Endocrinology & Metabolism, 2006) characterized CJC-1295 pharmacokinetics in a Phase 2 human trial, documenting sustained elevation of IGF-1 (a GH-dependent marker) after a single injection, with effects persisting for up to 6 days. Walker et al. (2007, Growth Hormone & IGF Research) demonstrated 2–10-fold increases in mean GH concentration over 28 days with weekly CJC-1295 administration. The foundational science for GH/sleep interaction comes from Van Cauter et al. (JAMA, 2000), showing that slow-wave sleep duration predicts nocturnal GH pulse amplitude, and that age-related loss of slow-wave sleep parallels GH decline. CJC-1295 is not specifically studied in sleep outcome trials; its connection to sleep quality is inferred from the GH/slow-wave sleep relationship, not demonstrated in dedicated sleep research.
Selective GHRP — clean GH pulse without cortisol elevation
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide growth hormone-releasing peptide (GHRP) that acts as a selective ghrelin receptor agonist to stimulate pituitary GH release. What distinguishes Ipamorelin from GHRP-2 and GHRP-6 — the other widely studied GHRPs — is its selectivity: it produces a pronounced GH pulse without the significant cortisol, prolactin, or ACTH elevations that the other GHRPs cause. Cortisol is a wakefulness-promoting stress hormone; a GHRP that elevates evening cortisol undermines the sleep-architecture benefit of increased nocturnal GH. Ipamorelin avoids this counterproductive effect, making it the mechanistically cleaner candidate for sleep-context GH research. Ipamorelin is frequently studied in combination with CJC-1295 because GHRH analogs and GHRPs act through complementary receptors (GHRH-R and GHSR-1a respectively), producing a synergistic GH response that exceeds what either compound produces alone.
Raun et al. (European Journal of Endocrinology, 1998, PMID 9719442) characterized Ipamorelin's selectivity profile in rats, documenting robust GH elevation with negligible cortisol, prolactin, ACTH, or TSH response — a selectivity advantage over GHRP-2 and GHRP-6. Smith et al. (2005, Best Practice & Research: Clinical Endocrinology & Metabolism) reviewed ghrelin receptor agonists including Ipamorelin as tools for GH axis research. No published human clinical trial has specifically evaluated Ipamorelin's effect on sleep architecture outcomes; the sleep-relevance inference is based on (a) the established GH/slow-wave sleep relationship, and (b) Ipamorelin's superior cortisol-selectivity profile. Like all GHRPs, Ipamorelin is a research compound with no FDA-approved indication.
Sleep peptides — particularly DSIP and Epitalon — are lower-volume compounds relative to mainstream research peptides like BPC-157 or CJC-1295. Lower market volume typically correlates with reduced quality competition and higher rates of substitution or underdosing in vendor batches. For DSIP especially, mass spectrometry confirmation of the nine-amino-acid sequence is important — HPLC purity alone does not confirm correct sequence identity. Epitalon's four-amino-acid sequence is short enough that robust MS data should always accompany HPLC results. Disclosed Labs maintains an independent COA corpus for sleep peptides drawn from Janoshik, ILS, Vanguard, and Freedom Diagnostics.
DSIP Regulatory Tracker
Live status of DSIP in the 2026 FDA PCAC review
Epitalon Regulatory Tracker
Live status of Epitalon in the 2026 FDA PCAC review
Best Peptides for Longevity
Epitalon, MOTS-c, DSIP, and five other anti-aging compounds
FDA Category 1 Guide
What the 2026 reclassification means for compounding
Best Peptides for Cognitive Function
Semax, Selank, Dihexa, P21 — nootropic peptide research
Best Peptides for Muscle Growth
CJC-1295, Ipamorelin, and GH secretagogues for muscle research
The most-studied peptides in sleep research fall into two mechanistic categories. The first targets sleep architecture directly: DSIP (Delta Sleep Inducing Peptide) is an endogenous nonapeptide that promotes slow-wave sleep (NREM stages 3–4) and modulates the hypothalamic-pituitary-adrenal (HPA) axis; Epitalon activates pineal melatonin synthesis, restoring circadian rhythm. The second targets growth hormone secretion that occurs during sleep: CJC-1295 (a GHRH analog) and Ipamorelin (a selective GHRP) amplify the natural nocturnal GH pulse that occurs during slow-wave sleep. All four are research compounds in the United States — not FDA-approved sleep aids.
DSIP (Delta Sleep Inducing Peptide; Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is an endogenous nine-amino-acid neuropeptide first isolated from rabbit cerebral venous blood by Monnier, Dudler, and Gächter in 1977 (Pflügers Archiv). When administered to animals, it reliably increased slow-wave (delta) sleep duration. Schoenenberger et al. (1978, European Neurology) reported improved sleep quality in human subjects in a double-blind crossover design. DSIP also modulates HPA axis activity — reducing corticotropin (ACTH) release and stress-induced cortisol elevation, which may explain some of its sleep-promoting effects. Key limitations: the original evidence base is from the 1970s–1980s; DSIP has a very short plasma half-life (measured in minutes) and its ability to cross the blood-brain barrier via peripheral administration is debated; no large-scale modern RCTs have been conducted.
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from Epithalamin, a polypeptide extract from the pineal gland. Unlike DSIP, which acts on sleep architecture directly, Epitalon works through the circadian clock: it stimulates the pineal gland to restore normal melatonin synthesis rhythms, which decline with age. Melatonin is the primary circadian signal that advances sleep onset and regulates the timing of sleep stages. Khavinson and Anisimov (Ageing Research Reviews, 2010) documented that Epitalon normalized pineal melatonin secretion in aged animals and small human cohorts, with downstream improvements in circadian rhythm organization. The mechanism is distinct from supplemental melatonin — rather than providing exogenous melatonin, Epitalon attempts to restore the gland's endogenous production. This circadian-restoration angle distinguishes Epitalon from other sleep compounds and makes it particularly studied in the context of age-related sleep deterioration.
CJC-1295 and Ipamorelin work through a different pathway from DSIP or Epitalon: they amplify growth hormone (GH) secretion, and GH is released in pulses preferentially during slow-wave sleep (NREM stage 3). Van Cauter et al. (JAMA, 2000) documented that the largest GH pulse of the day in healthy adults occurs within the first hour of sleep onset, and that aging-related decline in GH secretion correlates with reduced slow-wave sleep duration and quality. CJC-1295 is a GHRH (growth hormone-releasing hormone) analog that extends the duration of the pituitary GH response. Ipamorelin is a selective GHRP (GH releasing peptide) that amplifies GH release through the ghrelin receptor without the cortisol and prolactin elevation seen with GHRP-2 and GHRP-6. Combining a GHRH analog with a GHRP produces a synergistic GH pulse. The research interest in this combination for sleep centers on whether amplifying nocturnal GH output improves sleep architecture quality — particularly slow-wave sleep duration — in aging individuals whose GH secretion has declined.
The selectivity of Ipamorelin distinguishes it from other GH releasing peptides in the context of sleep research. GHRP-2 and GHRP-6 both stimulate GH release but also substantially elevate cortisol and prolactin — cortisol in particular is a stress hormone that promotes wakefulness and can fragment sleep architecture if elevated at night. Raun et al. (European Journal of Endocrinology, 1998) demonstrated that Ipamorelin produces a pronounced GH pulse with minimal effect on cortisol, prolactin, ACTH, or thyroid-stimulating hormone — the cleanest GH selectivity among the characterized GHRPs. This selectivity makes Ipamorelin the more logical candidate for sleep-context GH research, since the goal is GH amplification without the cortisol-mediated wakefulness that blunts sleep-architecture benefits from the other GHRPs.
Yes. DSIP is one of seven peptides on the FDA Pharmacy Compounding Advisory Committee (PCAC) docket for the July 23–24, 2026 advisory meeting. The PCAC reviews nominations for the 503A Bulk Drug Substances List and makes recommendations — the FDA issues any final rule later. In April 2026, the FDA removed DSIP (among 12 peptides) from Category 2 (the significant-safety-concern list), but this does not authorize compounding and does not place DSIP on the Category 1 (503A compoundable) list. DSIP's compounding eligibility depends on the outcome of the PCAC review and any subsequent FDA rulemaking.
CJC-1295 and Ipamorelin are among the 12 peptides the FDA removed from Category 2 (the significant-safety-concern list) in April 2026. This removal does not authorize compounding and does not place either peptide on the Category 1 (503A compoundable) list — it simply removes them from the list of peptides with significant safety concerns flagged by the FDA. Neither CJC-1295 nor Ipamorelin is on the July 2026 PCAC advisory docket. In the United States, both are sold as research chemicals for laboratory and scientific research use. Consult a licensed healthcare provider and regulatory attorney for current guidance on compounding access.
A reliable Certificate of Analysis (COA) for any sleep peptide should include: (1) HPLC purity — look for ≥98% for research-grade material; (2) Mass spectrometry (MS) confirmation of the molecular weight matching the expected sequence; (3) An identifiable third-party lab name — Janoshik, ILS, Vanguard, Freedom Diagnostics, and Kovera are common research labs; (4) A lot number matching the specific product batch you received. DSIP in particular is a low-volume compound with limited market competition — lower volumes typically correlate with higher substitution rates and lower quality consistency. The nonapeptide sequence is small enough that HPLC alone can miss subtle truncations; MS confirmation is especially important. Disclosed Labs maintains an independent COA corpus for sleep peptides across major vendors.
Disclosed Labs